Androgen deprivation therapy

European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer

The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...

Erleada for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease, European Commission approved

The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen...

Apalutamide improves overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer

Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical...

Prostate cancer: hormone therapy may raise risk of Alzheimer's, dementia

For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...

Olaparib in combination with Abiraterone delays disease progression in metastatic castration-resistant prostate cancer

Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...

Safety data from a phase II trial of Radium-223 dichloride plus Enzalutamide versus Enzalutamide alone in men with metastatic castration refractory prostate cancer

Radium-223 dichloride ( Ra-233; Xofigo ), a bone targeting alpha radiopharmaceutical, and Enzalutamide ( Xtandi ), are approved for metastatic...

Enzalutamide prolongs urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer

The PROSPER trial has shown a clinically and statistically significant improvement in metastasis-free survival ( hazard ratio, HR=0.292 [ 95%...

PROSPER trial: Enzalutamide reduces the risk of metastasis or death by 71% in men with non-metastatic castration-resistant prostate cancer

The results from the phase 3 PROSPER trial in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CRPC...

SPARTAN trial, Apalutamide, an androgen receptor inhibitor, improves median metastasis-free survival by more than two years in patients with non-metastatic castration-resistant prostate cancer

New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San...

Prostate cancer: link between androgen deprivation therapy and dementia

A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (...

Abiraterone acetate provides significant clinical benefit in patients with high-risk metastatic hormone-naïve prostate cancer, improving overall survival and radiographic progression-free survival

Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with...

Abiraterone for prostate cancer not previously treated with hormone therapy

STAMPEDE is a multigroup, multistage platform trial protocol investigating the efficacy of additional therapy at the time of inception of...

Metastatic prostate carcinoma: Enzalutamide, a hormone therapy, improves survival

In a phase III clinical trial, the hormone therapy Enzalutamide ( Xtandi ) extended survival in men with metastatic prostate...

Early prostate cancer: watchful waiting versus radical prostatectomy

Radical prostatectomy reduces mortality among men with localized prostate cancer; however, important questions regarding long-term benefit remain. Between 1989 and 1999,...

Increased survival in men with metastatic prostate cancer who receive Docetaxel when starting hormone therapy

According to early results from a randomized controlled clinical trial, men with hormone-sensitive metastatic prostate cancer who received the chemotherapy...